BUSINESS

AstraZeneca Looks to Keep No.1 Spot in Japan Oncology Space, Driven by Bispecific Antibodies

By Hayate Horiguchi February 7, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

AstraZeneca became the top oncology company in Japan last year, buoyed by its PD-L1 antibody Imfinzi (durvalumab) and EGFR inhibitor Tagrisso (osimertinib). The company is now poised to defend the crown by accelerating growth with the launch of new medicines…

To read the full story

Taking on Solid Tumors - 4: With 2 Late-Stage Assets in Wings, Will AstraZeneca Reshape CP Inhibitor Landscape?
June 10, 2025

BUSINESS

FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
Biomedix Takes Over Originator Data as Generics Face Supply, Information Challenge
February 13, 2026
Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
Nxera Gets US$1.8 Million Early-Stage Milestone from Centessa
February 13, 2026
Nxera Licenses GPCR Program to European VC-Backed Startup
February 13, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…